Blood Donor Written Statement of Understanding

Slides:



Advertisements
Similar presentations
The Role of the IRB An Institutional Review Board (IRB) is a review committee established to help protect the rights and welfare of human research subjects.
Advertisements

THE JOINT COMMISSION PATIENT BLOOD MANAGEMENT PERFORMANCE MEASURES
WH0 IS A PHLEBOTOMIST? Marjorie A. Di Lorenzo, MT(ASCP)SH Phlebotomy Technician Program Coordinator Nebraska Methodist College
Regulatory Challenges in the Cell Preparation Facility Adrian Gee Center for Cell & Gene Therapy Regulatory Challenges in the Cell Preparation Facility.
Transfusion Quiz. Q1. What colour blood tube is used for a group and cross match sample? Red Purple Pink Grey.
Development of Guidance Documents Jennifer Scharpf, M. P. H
Is Nucleic Acid Testing for Organ Donors the ‘Right’ Choice? Reference: Humara A, Morrisb M, Blumbergc R, et al. Nucleic acid testing (NAT) of organ donors:
Recently Issued OHRP Documents: Guidance on Subject Withdrawal and Draft Revised FWA Secretary’s Advisory Committee on Human Research Protections October.
CBER 1 Normal Source Plasma Donor Program Rosia E. Nesbitt, BS, SBB(ASCP), CQA(ASQ) Consumer Safety Officer CBER, OBRR, DBA September 16, 2009.
The Safety of the Blood Supply
IRB 101: Informed Consent Columbia University Medical Center IRB September 22, 2005.
Special Topics in IND Regulation
Current standards, donor safety, and blood supply
CBER Cooperative Manufacturing Arrangements (Contractors) Jennifer Jones Consumer Safety Officer CBER, OBRR, DBA September 15, 2009.
CDRH Software Regulation
CBER 1 Current standards, donor safety and blood supply Orieji Illoh, MD Office of Blood Research and Review Center for Biologics Evaluation and Research.
Role of Clinicians in Promoting Voluntary Blood Donation Dr. Anju Verma.
Parvovirus B19 NAT for Whole Blood and Source Plasma Introduction and Background Mei-ying W Yu, PhD DH/OBRR/CBER/FDA 75 th Blood Products Advisory Committee.
Donor Screening & Blood Collection. Donor Screening All blood comes from VOLUNTEER donors. Screening performed to ensure donor is healthy. Starts with.
CBER Hemoglobin/Hematocrit Acceptance Standards and Interdonation Interval in Blood Donors Introduction Blood Products Advisory Committee July 27, 2010.
CBER Hemoglobin/Hematocrit Acceptance Standards and Interdonation Interval in Blood Donors Summary and Questions for the Committee Blood Products Advisory.
CBER U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.
Topic 1. Validation of Procedures to Prevent Contamination and Cross-Contamination with TSE Agents of Human Tissue Intended for Transplantation TSEAC June.
FDA Guidance for Industry: Use of Serological Tests to Reduce the Risk of Transmission of Trypanosoma cruzi Infection in Whole Blood and Blood Components.
FDA and American Red Cross Blood Supply Safety & Protection Geoff Withnell, CQE, CQA, CQMgr System Design Engineer American Red Cross.
Workshop on Health Examination Surveys (HES) Legal and ethical issues Susanna Conti, M. Kanieff, G. Rago Istituto Superiore di Sanità (ISS) (National Public.
FDA’s Current Considerations of Parvovirus B19 Nucleic Acid Testing (NAT) Mei-ying W. Yu, PhD Division of Hematology CBER/FDA Extraordinary SoGAT Meeting.
CBER Review Considerations on Source Plasma Vaccination Programs Judy Ellen Ciaraldi BS, MT(ASCP)SBB, CQA(ASQ) CBER, OBRR, DBA September 16, 2009.
CBER Red Blood Cell Immunization Programs Judy Ellen Ciaraldi BS, MT(ASCP)SBB, CQA(ASQ) CBER, OBRR, DBA September 16, 2009.
Maria Rios, Ph.D. CBER/FDA Blood Products Advisory Committee May 1st, WNV Epidemiology & FDA’s Recommendations on the Use of NAT to Reduce the.
Challenges in evaluating and changing donor criteria Dr. Mindy Goldman Transfusion Medicine Residents April 30, 2008.
Blood Transfusion Done by : Mrs.Eman Rizk. Definition ( Blood Transfusion ) Is the process of transferring blood or blood-based products from one person.
Parvovirus B19 NAT Screening and Infectivity Mei-ying W Yu CBER/FDA SoGAT XVI Paul Ehrlich Institut July 03, 2003.
1 Donor’s Written Statement of Understanding Beth H. Shaz, MD Chief Medical Officer New York Blood Center Clinical Associate Professor Emory University.
The Journey of Blood. Blood- the life source Slide 1: Blood is a scarce and vital national resource which cannot be synthesized. About 80 million unit.
Current Considerations on Plasma for Further Manufacturing Obtained from Whole Blood Donors Alan E. Williams, Ph.D. Associate Director for Regulatory Affairs,
Apheresis Blood Components
FDA Recommendations: Sampling Plans for Blood Establishments Lore Fields MT(ASCP)SBB Consumer Safety Officer OBRR/CBER/FDA October 19, 2012.
REGULATIONS FOR BLOOD and BLOOD PRODUCTS JILL HOAG BS, SBB(ASCP) CQA(ASQ) AABB STAFF LEAD ASSESSOR 1.
Leukocyte-Reduced Blood Components Lore Fields MT(ASCP)SBB Consumer Safety Officer, DBA, OBRR, CBER September 16, 2009.
CBER’s Blood Safety Team Blood Products Advisory Committee 01 May 2008 Jonathan C. Goldsmith, MD Office of Blood Research and Review.
April The American Red Cross experience with TRALI Richard J Benjamin MD PhD Chief Medical Officer American Red Cross, Biomedical Headquarters Washington.
CBER September 16, 2009 Review Considerations on Disease State Donor Programs Hoi-may Wong, BS, MT(ASCP)SBB Consumer Safety Officer CBER, OBRR, DBA.
12 th Annual FDA & the Changing Paradigm for Blood Regulation – 01/16/2009 – Las Vegas, NV – Gilliam B. Conley 1 FDA perspective on “Where are we? Where.
Abbreviated Donor History Questionnaire: Background and Introduction Sharyn Orton, Ph.D. OBRR/CBER/FDA Blood Products Advisory Committee March 2005.
Blood Center Experience with Double Red Cell Collections by Apheresis: Adverse Events and Impact on Capacity Brian Custer, Hany Kamel, Marj Bravo Peter.
Revised Recommendations for the Assessment of Donor Suitability: West Nile Virus Sharyn Orton, Ph.D. OBRR/CBER/FDA Blood Products Advisory Committee Meeting.
Update on Transfusion Safety Management Systems Blood Products Advisory Committee Meeting, March 9, 2006 Linda Weir, CSO, CBER/OBRR/DBA.
Dispensary and Administration Site Information Presentation.
Management of Donors and Units that Test HBV NAT Positive: Current Considerations July 21, 2005 BPAC Meeting Robin Biswas, M.D. FDA/CBER/OBRR/DETTD.
What Institutional Researchers Should Know about the IRB Susan Thompson Senior Research Analyst Office of Institutional Research Presented at the Texas.
RISK COMMUNICATION APPROACH TSEAC 15 December 2006 Mark Weinstein, Ph.D. FDA, Center for Biologics Evaluation and Research.
Modeling Risk of vCJD in US Donors – Residual Risk and Efficiency of Donor Deferral Alan E. Williams, Ph.D. Director, Division of Blood Applications Office.
Minimizing the Risks of TSE Agents in Human Tissues Melissa A. Greenwald, M.D. Division of Human Tissues Office of Cellular, Tissue and Gene Therapies;
HHS Secretary’s Advisory Committee on Blood Safety and Availability Summary for FDA’s BPAC July 2010 Jerry A. Holmberg, Ph.D. Senior Advisor for Blood.
Donor Suitability and Blood and Blood Product Safety in Cases of Known or Suspected West Nile Virus Infection - Update - Alan E. Williams, Ph.D. Director,
Human Specimen Repositories Requirements of 21 CFR Parts 50 & 56 PRIM & R May 5, 2004 Sally A. Hojvat, Ph.D. Director of Microbiology Devices Office of.
Proposed Workshop: Hemoglobin Standards and Maintenance of Iron Stores in Blood Donors Blood Product Advisory Committee April 29, 2011.
DEPARTMENT OF HEALTH CENTER FOR BIOLOGICS AND HUMAN SERVICESEVALUATION and RESEARCH AND HUMAN SERVICES EVALUATION and RESEARCH Update on OCTGT Guidance.
Allogeneic donor selection and blood collection by Mohammed Abu-basha 1.
Transfusion Related Acute Lung Injury (TRALI)
Confidential Unit Exclusion Donors may be given the opportunity to indicate confidentially whether their blood is or is not suitable for transfusion to.
FDA’s vCJD Risk Communication on US Plasma- Derived Factor VIII and UK Plasma-Derived Factor XI BPAC April 27, 2007 Mark Weinstein, Ph.D. FDA, Center for.
Informed Consent Presented by Marian Serge, RN. Goals Informed consent process and form Title 38 CFR , Common Rule required elements and additional.
Informed Consent for Transfusion
2015 Haemovigilance Report Tables and Figures
Erythrocytapheresis.
Living Donor Committee Spring 2014
Living Donor Committee Spring 2014
COMPARATIVE STUDY OF ADVERSE DONOR EVENTS IN VOLUNTARY AND REPLACEMENT WHOLE BLOOD DONORS: NEED OF ROBUST DONOR HEMOVIGILANCE PROGRAM Dr Lubna Naseer,
Presentation transcript:

Blood Donor Written Statement of Understanding Introduction Orieji Illoh, MD Office of Blood Research and Review CBER/FDA Blood Products Advisory Committee April 29, 2011

Outline Introduction Issues to be considered Donor consent: Current status FDA requirements or recommendations AABB standards ACBSA recommendations “Written statement of understanding” (WSU) Elements as outlined in the 2007 proposed rule Public comments to the proposed rule Elements of the written statement of understanding Educational material Risks and hazards of blood donation Questions for the committee Speakers and topics

Introduction About 10 million allogeneic donors provided ~17 million donations of Whole Blood and Red Blood Cells in 2008. The blood donation process is highly safe but adverse reactions can occur. FDA has regulations for donor consent in Source plasma, plateletpheresis and plasmapheresis donors. The practice of donor consent for whole blood donors varies. 3

Blood donation process 1 2 3 4 Registration Donor provides identification and demographic information Donor reads information about blood donation (Educational material) Donor consents to blood donation Health history and limited physical examination Health history questions asked by blood center staff Blood pressure, pulse and hemoglobin levels are checked Donation Arm is cleansed Blood is drawn (6-10 minutes) Needle is removed Recovery Rest ~ 15mins Snacks Average donation process takes just under one hour

Issues for consideration Proposed “Written Statement of Understanding” for Whole Blood donors Content How to administer When to administer Does not include informed consent for research studies. Including collection of repository samples.

Donor consent: Current status

FDA requirements or recommendations Source Plasma 21CFR 640.61 “Guidance on Informed Consent Recommendations for Source Plasma Donors Participating in Plasmapheresis and Immunization Programs” Plateletpheresis and plasmapheresis 21 CFR 640.21(c) and 21CFR 640.31(b) “Guidance for Industry and FDA Review Staff: Collection of Platelets by Automated Methods” Apheresis red blood cell donations “Guidance for Industry: Recommendations for Collecting Red Blood Cells by Automated Apheresis Methods

AABB Standard for Donor Consent Obtained on the day of donation and presented in understandable terms Information provided regarding: Risks of the procedure. Tests performed to reduce the transmission of infectious diseases to the allogeneic recipient. An opportunity provided to ask questions and to give or refuse consent for donation. AABB. Standards for Blood Banks and Transfusion Services. 27th ed.

Advisory Committee for Blood Safety and Availability: December 2008 Donor consent is generally adequate but lacks consistency. Include in consent forms The effects of repeat donation on the donor population. The gender specific effects of iron deficiency on donors. The effects of collecting blood from anemic men using current donation thresholds. The disproportionate prevalence of adverse events in the youngest donors. Consider The method and frequency of effective informed consent for repeat donations

FDA Proposed Rule: Written Statement of Understanding

“Written Statement of Understanding” - definition The term “Written Statement of Understanding” is used as a general term to differentiate it from informed consent for research as defined in 21CFR 50.25

2007 Proposed Rule: WSU The donor has received and reviewed the educational material. The donor agrees not to donate if the donation could result in a potential risk to the safety, purity, or potency of the blood supply. A sample of the donor’s blood will be tested for specified relevant transfusion-transmitted infections and for syphilis.

2007 Proposed Rule: WSU If any of the tests is reactive, the sample of blood will be tested further. If the donation is determined to be not suitable or if the donor is deferred from donation, the donor’s record must identify the donor as ineligible to donate and the donor must be notified. The hazards and risks of the donation procedure are explained. The donor has the opportunity to ask questions and withdraw consent at any time.

2007 Proposed Rule: WSU Blood establishments would need to provide and ensure that the written statement to the donor: Is read and signed before each donation. Is written in clear terminology. Does not include language that would waive any of the donor's legal rights. FDA rulemaking is not intended to preempt state laws regarding donor consent for minors.

Proposed Rule: WSU Representative comments from industry Agreement that donors should be adequately informed about the blood donation process and that there should be documentation that the donor has been so informed. Concern about how signature will be obtained. Consider electronic acknowledgement. Provide guidance that provides recommendations for compliance with this rule.

Proposed Rule: Written Statement of Understanding: Selected elements Educational materials Risks and hazards of donation

WSU: Educational materials AABB introduced educational materials in 1984. Current FDA recommendations for HIV education published in the 1992 memorandum. Incorporated into the AABB educational materials. AABB educational material version 1.3

WSU: Educational materials Information about the behaviors that increase risks of relevant transfusion-transmitted infections. Signs and symptoms of such infections, and the consequent risk to the safety of the blood and blood component. Instructions for donors to self-defer if they determine that they have participated in an increased-risk behavior for, or show signs or symptoms of that relevant transfusion-transmitted infection.

WSU: Educational materials This information may be provided in oral, written, or multimedia form in a manner designed to be understood by the donor. FDA may provide additional guidance in the future.

WSU: Risks and hazards of Blood donation About 3 – 10% of blood donors will experience an adverse reaction Eder A et al. Transfus Med Rev. 2009 Jul;23(3):205-20. Severe adverse donor reaction rate in 2008 = 0.09% collection procedures Whitaker BI et al. The 2009 National Blood Collection and Utilization Survey (presented at the 2010 AABB meeting)

Risks and hazards of Whole Blood donation Minor Major Long term Dizziness Presyncope Bruises Hematomas Allergic Syncope with loss of consciousness or injury Nerve damage Arterial puncture Iron deficiency with or without anemia

Risks and hazards of blood donation Study: Post donation interview of 1000 Whole Blood donors % donor reaction rate AEs = Adverse effects Arm injuries Systemic reactions Total AEs Bruise Sore arm Hematoma Sensory changes Fatigue Vasovagal Nausea and vomiting 36.1 22.7 10.0 1.7 0.9 7.8 5.3 1.1 Newman et al. Transfusion. 2003 May;43(5):598-603

American Red Cross: 2006 hemovigilance data Rates of complications associated with allogeneic Whole Blood donation ~ 6 million whole blood donations ~ 349 complications/ 10,000 donations Major reaction rate (7.4/10,000) Most complications were minor Hematomas (~75/10,000) Presyncopal (~258/10,000) Eder et al. Transfusion. 2008 Sep;48(9):1809-19

Blood donor fatalities FDA donor fatality reports: FY 2005 through FY 2009. In 2009, Whole blood fatalities 2 cases - donation ruled out 1 case - donation not ruled out but no causal relationship http://www.fda.gov/BiologicsBloodVaccines/Safety Availability/ReportaProblem/TransfusionDonationFatalities

Questions for the committee Please comment on the seven proposed elements of the written statement of understanding as listed in FDA’s 2007 proposed donor eligibility rule. Does the Committee agree that the data support a need for minimum standards for the explanation of the risks and hazards of Whole Blood donation to the donor? Please comment on what methods are acceptable for presenting the written statement of understanding to the donor, and how the donor should acknowledge receipt of this statement.

Questions for the committee Please comment: When should blood establishments administer the written statement of understanding? Before donor questions? Before physical examination? Before phlebotomy? Please comment: How often should blood establishments administer the written statement of understanding to Whole Blood donors?

Speakers Christine Grady, MSN, PhD : National Institutes of Health. Clinical Center An overview of informed consent Beth Shaz, M.D.: New York Blood Center Evaluation of informed consent forms for adults and minors for whole blood donation used by United States blood centers. Ronald Domen, M.D.: Penn State Milton S. Hershey Medical Center The informed consent process in whole blood donation.